Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial
Daiichi Sankyo
Fabrice André; Yeon Hee Park; Sung-Bae Kim; Toshimi Takano; Seock-Ah Im; Giuliano Borges; Joao Paulo Lima; Sercan Aksoy; Joaquin Gavila Gregori; Michelino De Laurentiis; Giampaolo Bianchini; Rebecca Roylance; Yasuo Miyoshi; Anne Armstrong; Rajni Sinha; Manuel Ruiz Borrego; Elgene Lim; Johannes Ettl; Rinat Yerushalmi; Flora Zagouri; Francois P Duhoux; Tanja Fehm; Dhiraj Gambhire; Jillian Cathcart; Cai Wu; Changan Chu; Anton Egorov; Ian Krop